VYGR 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
VYGR 近期報酬表現
-2.32%
Voyager therapeutics inc
-0.77%
同產業平均
0.12%
S&P500
與 VYGR 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
XENE | Xenon pharmaceuticals inc | 3 分 | 1 分 | 2 分 | 3 分 | 1 分 | |
TSBX | Turnstone biologics corp | - | 2 分 | 2 分 | 1 分 | 1 分 | |
ZVSA | Zyversa therapeutics inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
MURA | Mural oncology plc | - | 2 分 | - | - | 1 分 | |
CRGX | Cargo therapeutics inc | - | 3 分 | 3 分 | 3 分 | 1 分 |
- XENE Xenon pharmaceuticals inc價值 3 分趨勢 1 分波段 2 分籌碼 3 分股利 1 分查看更多
VYGR 公司資訊
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company's pipeline includes programs for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich's Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer's disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.